“BA.2.75 is a scariant. It’s not spreading anywhere besides a couple of provinces in India without BA.5 to compete with,” Eric Topol, MD, founder and director of the Scripps Research Translational Institute in San Diego, said in a July 19 tweet, citing a graph based on data from global data-sharing virus platform GISAID that indicates the strain hasn’t spread much outside of several states in India. “There will be other new variants to be concerned about, but it doesn’t look like this is one of them.”
Early disease surveillance data showed at least 18 cases of the strain have been identified in seven U.S. states as of July 20. Gobally, researchers have identified 201 cases in at least 10 countries.
“BA.2.75 has certain mutations that have attracted global attention,” Rajeev Jayadevan, MD, co-chair of the National Indian Medical Association, wrote in a tweet. “However, from limited samples available, there are no reports yet of severe disease or excessive spread.”
The variant first caught experts’ eye for appearing to have a large number of mutations that may make it more adept than BA.5 at spreading quickly and evading immune protection.
The World Health Organization has not named it a variant of concern or officially assigned it a name and is closely tracking data on the strain.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
